Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab combined with daratumumab or lenalidomide in elderly patients with newly diagnosed multiple myeloma
2024-514101-65-00Phase 2Authorised
- Sponsor
- CHU de Lille
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of teclistamab, daratumumab and lenalidomide, sponsored by CHU de Lille. Planned start Jul 2024; status: authorised.
02
Drugs
teclistamabdaratumumablenalidomide
Beyond the preview
Go deeper on 2024-514101-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514101-65-00.